Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development

Inflammatory Bowel Disease

Breaking the therapeutic ceiling in drug development in ulcerative colitis

Lancet Gastroenterol Hepatol

Alsoud D, Verstockt B, Fiocchi C, Vermeire S

doi: 10.1016/S2468-1253(21)00065-0

Inflammatory Bowel Disease

Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis

Scand J Gastroenterol.

Dignass AU, Siegmund B, Goertz R, Schneidewind G, Fanter L

doi: 10.1080/00365521.

RECOMMENDED

Inflammatory Bowel Disease

DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis

J Crohns Colitis.

Rowan CR, Cullen G, Mulcahy HE, Sheridan J, Moss AC, Ryan EJ, Doherty GA

doi: 10.1093/ecco-jcc/jjz067.

Inflammatory Bowel Disease

Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis ? An international multicentric retrospective study in 72 patients

J Crohns Colitis.

Frontali A, Cohen L, Bridoux V, Myrelid P, Sica G, Poggioli G, Espin E, Beyer-Berjot L, Laharie D, Spinelli A, Zerbib P, Sampietro G, Frasson M, Louis E, Danese S, Fumery M, Denost Q, Altwegg R, Nancey S, Michelassi F, Treton X, Panis Y

doi: 10.1093/ecco-jcc/jjaa107.

Inflammatory Bowel Disease

ACG Clinical Guideline: Ulcerative Colitis in Adults

Am J Gastroenterol.

Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD

doi: 10.14309/ajg.

Inflammatory Bowel Disease

Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis

Inflamm Bowel Dis.

Adedokun OJ, Gunn GR 3rd, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P5, Shankar G

doi: 10.1093/ibd/izz003.

Inflammatory Bowel Disease

Small molecule oral targeted therapies in ulcerative colitis

Lancet Gastroenterol Hepatol.

Shivaji UN, Nardone OM, Cannatelli R, Smith SC, Ghosh S, Iacucci M

doi: 10.1016/S2468-1253(19)30414-5.

Inflammatory Bowel Disease

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

J Crohns Colitis

Winthrop KL, Loftus EV Jr, Baumgart DC, Reinisch W, Nduaka CI, Lawendy N, Chan G, Mundayat R, Friedman GS, Salese L, Thorpe AJ, Su C

doi: 10.1093/ecco-jcc/jjaa233

Inflammatory Bowel Disease

Non-biological therapeutic management of ulcerative colitis

Expert Opin Pharmacother.

Mezzina N, Campbell Davies SE, Ardizzone S

doi: 10.1080/14656566.

Related content

Breaking the therapeutic ceiling in drug development in ulcerative colitis

Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis

DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis

Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis ? An international multicentric retrospective study in 72 patients

ACG Clinical Guideline: Ulcerative Colitis in Adults

Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis

Small molecule oral targeted therapies in ulcerative colitis

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

Non-biological therapeutic management of ulcerative colitis